Exploring the Neurological Questions Surrounding GLP-1 Drugs
researchers are exploring how these drugs may affect more than appetite, blood sugar, and weight loss. A Washington Post article updated on May 28, 2026, and distributed through Yahoo News examined emerging research into how GLP-1 medications may interact with the brain, raising questions about their potential influence on areas involved in appetite, reward, motivation, and emotion.
While the article discussed intriguing findings, it also highlighted an important reality: scientists are still learning about the full effects of these medications throughout the body.
To help readers better understand the topic, Shore Healthy Living spoke with Reeva Salkin, DNP, APN-BC, ANP-BC , a neurology specialist with Shore Physicians Group. Salkin was not involved in the research discussed in the article but shared her professional perspective on the questions being raised.
Originally developed to help manage Type 2 diabetes, GLP-1 receptor agonists have become widely known for their effectiveness in helping patients lose weight. For many people, these medications have produced significant health benefits, including improved blood sugar control and reduced risk factors for chronic disease.
“These medications were originally developed for diabetes management and are now widely recognized for their weight-loss benefits,” Salkin explained. “What we’re learning is that their effects may not be limited to the stomach and digestive system.”
Because the medications affect pathways involved in appetite, glucose metabolism, and inflammation, researchers are studying whether they may also influence certain functions within the brain. Some patients have reported symptoms such as brain fog, dizziness, fatigue, headaches, or changes in mood, but determining the cause can be challenging.
“The challenge is determining what’s actually causing those symptoms,” Salkin said. “Are they related to the medication’s effects on the brain, or are they the result of reduced food intake, dehydration, changes in blood sugar, electrolyte imbalances, or nutritional deficiencies?”
That distinction is important. Because GLP-1 medications suppress appetite, some patients consume significantly fewer calories than they did previously. Rapid weight loss and reduced nutritional intake can sometimes lead to symptoms that feel neurological but may actually be related to hydration, blood sugar, or nutrition.
“If someone comes in experiencing brain fog, dizziness, weakness, or fatigue, we need to go back to basics,” Salkin said. “We need to evaluate blood sugar levels, blood pressure, hydration, protein intake, and overall nutritional status before drawing conclusions.”
Researchers are also investigating the potential long-term effects of GLP-1 medications. In addition to diabetes and weight management, these drugs have been studied for possible applications in conditions such as Alzheimer’s disease. While some findings have generated interest, research remains ongoing.
At the same time, rare side effects continue to be identified. One recently recognized condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), has been associated with a very small number of users and can affect vision. Although the risk appears to be extremely low, it serves as a reminder that all medications carry both benefits and risks.
For Salkin, the takeaway is not fear or alarm.
“The goal isn’t to create fear,” she said. “The goal is informed decision-making.”
For many patients, GLP-1 medications can be life-changing. The key is understanding that these are powerful medications that should be used thoughtfully and under medical supervision. Patients who experience new symptoms should discuss them with their healthcare provider rather than making assumptions or attempting to manage concerns on their own.
“We’re still learning,” Salkin said. “That’s why regular monitoring and communication with your healthcare provider are so important.”
As science continues to evolve, that partnership between patients and providers remains the best way to make informed decisions about treatment and long-term health.
Reeva Salkin, DNP, APN-BC, ANP-BC is a neurology specialist with Shore Physicians Group who treats patients age 18 and older. She sees patients at 700 Shore Road, First Floor, Somers Point, NJ 08244. To schedule an appointment, call 609-365-6202.
